文献速递肿瘤 PET/CT

68Ga-NC-BCH全身PET显像可快速靶向胃肠道肿瘤患者的Claudin18.2病灶

68Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients.
PubMed 文献 · J Nucl Med · 2024-06-03

本研究为68Ga-NC-BCH(一种基于单域抗体的PET显像剂)的首次人体研究,旨在确定其体内生物分布、代谢、辐射剂量学、安全性及定量胃肠道肿瘤患者claudin-18异构体2(CLDN18.2)表达的潜力。方法包括探针合成、临床前评估及在全身PET/CT扫描仪上对晚期胃肠道肿瘤患者进行试点队列的转化研究。结果显示68Ga-NC-BCH制备稳定,临床前显示快速血液清除、对CLDN18.2高亲和力及高特异性摄取;患者中胃和肾高摄取、胰腺轻微摄取;与18F-FDG相比,68Ga-NC-BCH在不同CLDN18.2表达水平的病灶中摄取有显著差异;PET SUV与CLDN18.2表达呈明确相关性,提示其可作为伴随诊断工具。

要点

  • 68Ga-NC-BCH制备稳定,放射化学性质良好。
  • 临床前显示快速血液清除、对CLDN18.2高亲和力及高特异性摄取。
  • 患者中胃和肾高摄取、胰腺轻微摄取;PET SUV与CLDN18.2表达呈明确相关性。

核心结论

  • PET SUV与CLDN18.2表达之间检测到明确相关性,提示68Ga-NC-BCH PET可作为伴随诊断工具用于优化靶向CLDN18.2的肿瘤治疗。

研究设计与样本

  • 首次人体研究:先合成68Ga-NC-BCH并在人胃腺癌细胞系及异种移植小鼠模型中进行临床前评估,随后在全身PET/CT扫描仪上对晚期胃肠道肿瘤患者试点队列进行转化研究。

主要发现

  • 68Ga-NC-BCH制备稳定,放射化学性质良好。
  • 临床前评估显示68Ga-NC-BCH快速血液清除、对CLDN18.2高亲和力,并在CLDN18.2阳性细胞及异种移植小鼠模型中高特异性摄取。
  • 68Ga-NC-BCH在胃和肾高摄取,胰腺轻微摄取。
  • 与18F-FDG相比,68Ga-NC-BCH在不同CLDN18.2表达水平的病灶中摄取有显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-labeled nanobody (68Ga-NC-BCH) is a single-domain antibody-based PET imaging agent. We conducted a first-in-humans study of 68Ga-NC-BCH for PET to determine its in vivo biodistribution, metabolism, radiation dosimetry, safety, and potential for quantifying claudin-18 isoform 2 (CLDN18.2) expression in gastrointestinal cancer patients. Methods: Initially, we synthesized the probe 68Ga-NC-BCH and performed preclinical evaluations on human gastric adenocarcinoma cell lines and xenograft mouse models. Next, we performed a translational study with a pilot cohort of patients with advanced gastrointestinal cancer on a total-body PET/CT scanner. Radiopharmaceutical biodistribution, radiation dosimetry, and the relationship between tumor uptake and CLDN18.2 expression were evaluated. Results: 68Ga-NC-BCH was stably prepared and demonstrated good radiochemical properties. According to preclinical evaluation,68Ga-NC-BCH exhibited rapid blood clearance, high affinity for CLDN18.2, and high specific uptake in CLDN18.2-positive cells and xenograft mouse models. 68Ga-NC-BCH displayed high uptake in the stomach and kidney and slight uptake in the pancreas. Compared with 18F-FDG, 68Ga-NC-BCH showed significant differences in uptake in lesions with different levels of CLDN18.2 expression. Conclusion: A clear correlation was detected between PET SUV and CLDN18.2 expression, suggesting that 68Ga-NC-BCH PET could be used as a companion diagnostic tool for optimizing treatments that target CLDN18.2 in tumors.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Qi C, Guo R, Chen Y, et al. 68Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients. J Nucl Med. 2024. PMID: 38604764. doi:10.2967/jnumed.123.267110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。